SNGX SOLIGENIX, INC.

SNGX financial statements, revenue, balance sheet, cash flow, and SEC filings

CIK: 812796 Exchange: Nasdaq SIC: 2834 (Pharmaceutical Preparations) Latest filing: 10-Q filed Nov 6, 2026 Data checked: Nov 10, 2026
Showing 3 of 16 annual and 0 of 65 quarterly periods. Full history available with a free account or via API.

▼ Company Profile

Filer Category
Non-accelerated filer<br>Smaller reporting company
Entity Type
Operating
Public Float
$4.59M (Jun 2025)
Industry (SIC)
2834 Pharmaceutical Preparations
Incorporated
DE
Fiscal Year End
December (1231)
Phone
609-538-8200
EIN
411505029
Headquarters
PRINCETON, NJ, 08540
Public Float History
Market value of shares held by public investors, reported in annual DEI filings.
Former Names: SOLIGENIX, INC. (2009–2026) · DOR BIOPHARMA INC (2002–2009) · ENDOREX CORP (1996–2001) · IMMUNOTHERAPEUTICS INC (1995–1996)

▼ Key Metrics (TTM)

As of Sep 30, 2026
Financials
Revenue
-
Net Income
$-8.83M
Total Assets
$9.46M
Total Equity
$6.26M
Total Debt
-
Free Cash Flow
-
Ratios
Return on Equity
-141.1%
Return on Assets
-93.2%
Current Ratio
3x

▼ FY 2025 Summary Analysis

Annual report ending Dec 31, 2025

Overview and Growth

SOLIGENIX, INC. recorded fiscal 2025 net loss of $11.08M. The company reported diluted EPS of -$2.14, adding a shareholder-level measure to the absolute income figures considered below. Diluted shares averaged 5.19M; this is the reported share base over which the company’s diluted per-share earnings were spread. Compared with 1.66M diluted shares in fiscal 2024, the current 5.19M base was 212.5% higher. The company employed $9.24M of total assets, the balance-sheet base supporting its current operating and cash-flow results.

Profitability

The reported operating result was an operating loss of $11.85M, reflecting costs that exceeded gross profit. After all below-operating-line items, the company recorded a net loss of $11.08M for the fiscal year. Before income taxes, the company recorded a loss of $11.59M, bridging the operating result to the final net loss. The reported tax benefit was $506.62K, favorably bridging the pretax and after-tax results. The loss-to-equity relationship was 209.4%, placing the bottom-line deficit against shareholder capital. Relative to total assets, the net loss represented 120.0%. The net loss widened to $11.08M from $8.27M in fiscal 2024.

Liquidity and Capital Structure

The company held $9.24M of assets against $3.94M of liabilities and $5.29M of equity, revealing how the asset base was financed. Current assets were $8.85M against $3.70M of current liabilities, framing the resources and obligations classified within the near-term balance-sheet horizon. The current ratio was 2.39x, with current assets exceeding current liabilities and providing a short-term liquidity cushion. Reported cash and equivalents were $7.94M, separating immediately recognizable cash resources from the rest of the current-asset base. The cash balance equaled 214.5% of current liabilities, showing how much near-term coverage came from cash alone. Equity equaled 57.3% of assets, showing the shareholder-capital layer within the company’s balance sheet. Relative to total assets, liabilities measured 42.7%, complementing the separate equity-based view of the company’s capital structure. Cash and equivalents equaled 85.9% of total assets, showing the liquid cash component within the company’s broader resource base. The asset base changed 3.0% from $8.97M in fiscal 2024, leaving current total assets higher year over year. Reported equity changed 28.5% from $4.12M in fiscal 2024, placing the current capital base higher year over year. The reported cash balance changed 1.5% from $7.82M in fiscal 2024, ending higher year over year.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $10.27M, showing that operations absorbed cash during the period. Capital spending of $5.88K added to the period’s operating cash use, reinforcing the overall cash deficit after investment for the year. Negative free cash flow was $10.27M, leaving a cash deficit after capital spending and reducing financial flexibility. Relative to total assets, the post-investment cash deficit measured 111.2%. Cash absorbed by operations increased from $8.40M in fiscal 2024 to $10.27M.
Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated .
Sources and calculation details

Reported values are preserved. Derived values use the listed inputs; unavailable inputs remain blank.

Field-level sources for this historical record are unavailable until it is rebuilt from SEC facts.

Annual financial statements for SOLIGENIX, INC.
Metric FY2025 📄 FY2024 📄 FY2023 📄
Income Statement
REVENUE
Revenue - $119.37K $839.36K
Cost of Revenue - $119.37K $742.05K
Gross Profit - $0 $97.31K
OPERATING EXPENSES
R&D Expense $7.49M $5.22M $3.31M
SG&A Expense $4.36M $4.22M $4.48M
Other Operating Expenses (derived) - $0 $0
Operating Income $-11.85M $-9.44M $-7.70M
NON-OPERATING INCOME / EXPENSE
Other Income/Expense $-11.69K $549.83K $-161.46K
Pretax Income $-11.59M $-8.68M $-7.91M
Income Tax $-506.62K $-409.11K $-1.77M
Net Income $-11.08M $-8.27M $-6.14M
PER SHARE & SUPPLEMENTAL
Diluted EPS $-2.14 $-4.98 $-12.66
Diluted Shares 5.19M 1.66M 485.00K
Balance Sheet
ASSETS
Cash & Equivalents $7.94M $7.82M $8.45M
Other Current Assets $894.31K $905.27K $866.01K
Current Assets $8.85M $8.83M $9.51M
PP&E (Net) $8.77K $6.11K $11.93K
Noncurrent Assets $386.51K $137.85K $290.01K
Total Assets $9.24M $8.97M $9.80M
LIABILITIES
Accounts Payable $1.12M $667.90K $1.11M
Other Current Liabilities $272.09K $1.22M $424.22K
Current Liabilities $3.70M $4.85M $6.15M
Long-term Debt - $0 $1.01M
Other Noncurrent Liabilities (derived) - $0 $111.86K
Noncurrent Liabilities $244.12K $0 $1.12M
Total Liabilities $3.94M $4.85M $7.27M
EQUITY
Common Stock $10.09K $2.51K $649
Additional Paid-in Capital $250.29M $238.04M $228.20M
Retained Earnings $-245.05M $-233.97M $-225.70M
Accumulated OCI $45.79K $45.79K $22.24K
Total Equity $5.29M $4.12M $2.52M
Total Liabilities & Equity $9.24M $8.97M $9.80M
SUPPLEMENTAL
Shares Outstanding 10.09M 2.51M 648.76K
Check: A − (L + E + Temp. Equity) - - -
Cash Flow Statement
Cash from Operations $-10.27M $-8.40M $-8.60M
Capital Expenditures $5.88K - -
Cash from Investing $-5.88K $0 $0
Cash from Financing $10.39M $7.76M $3.66M
Free Cash Flow $-10.27M - -
Beginning Cash (CFS) $7.82M $8.45M $13.36M
Net Change in Cash $116.64K $-641.53K $-4.94M
Effect of FX on Cash $0 $14.89K $27.15K
Calculated Ending Cash $7.94M $7.82M $8.45M
Cash per BS $7.94M $7.82M $8.45M
Cash scope difference (CFS − BS) - - -
Cash per CFS $7.94M $7.82M $8.45M

Create a free account to see full history, quarterly data, charts, CSV downloads, and API access.

Create Free Account Log In
🔒

Quarterly data and charts require a free account

Get access to 8 quarters of data, interactive charts, CSV downloads, and API access.

▼ Frequently Asked Questions

Is SOLIGENIX, INC. profitable?

No. SOLIGENIX, INC. reported $-8.83M in net income for trailing twelve months. Profitability data is based on the company's most recent annual report filed with the SEC.